arsenic has been researched along with Duncan Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bobé, P; Chelbi-Alix, MK | 1 |
| Colomer, D; Montserrat, E; Villamor, N | 1 |
| Benihoud, K; Bobé, P; Bonardelle, D; Chelbi-Alix, MK; Opolon, P | 1 |
1 review(s) available for arsenic and Duncan Disease
| Article | Year |
|---|---|
Cytotoxic effects of B lymphocytes mediated by reactive oxygen species.
Topics: 2-Methoxyestradiol; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; B-Lymphocytes; Benzodiazepines; Cell Death; Estradiol; Hexanones; Humans; Lymphoproliferative Disorders; Oxidative Stress; Oxides; Reactive Oxygen Species; Rituximab; Signal Transduction | 2004 |
2 other study(ies) available for arsenic and Duncan Disease
| Article | Year |
|---|---|
[New therapeutic perspectives for arsenic: from acute promyelocytic leukemia to autoimmune diseases].
Topics: Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Autoimmune Diseases; Disease Models, Animal; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Mice; Oxides | 2008 |
Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice.
Topics: Animals; Antibodies, Antinuclear; Antigen-Antibody Complex; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cytokines; Drug Evaluation, Preclinical; Enzyme Activation; fas Receptor; Glutathione; Humans; Lupus Erythematosus, Systemic; Lymphocyte Activation; Lymphoproliferative Disorders; Mice; Mice, Inbred MRL lpr; Nitric Oxide; Oxidation-Reduction; Oxides; Syndrome | 2006 |